BioHF Score: Explanation and Clinical Context
The BioHF Score (modelled after the BCN Bio-HF Calculator) integrates clinical variables (age, sex, NYHA class, LVEF, serum sodium, eGFR, hemoglobin, loop diuretic dose, and therapy status such as β-blocker, ACEI/ARB, statin) together with key biomarkers (NT-proBNP, high-sensitivity troponin T, and soluble ST2) to estimate individual mortality risk at 1, 2 and 3 years in patients with heart failure. By incorporating biomarkers that reflect myocardial stretch (NT-proBNP), myocyte injury (hs-cTnT) and myocardial fibrosis/ventricular remodelling (sST2), this tool allows a more nuanced risk stratification beyond conventional clinical scores. In clinical terms: a higher score (and thus higher estimated risk) should prompt closer monitoring, more intensive management (optimization of guideline-directed therapies), and may justify consideration of advanced therapies or earlier referral.
Reference:
Lupón J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: the Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator). PLoS One. 2014;9(1):e85466. doi:10.1371/journal.pone.0085466. :contentReference[oaicite:4]{index=4}